Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 871 AL 885

Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson's Disease

Zhang Y, Tan F, Xu P, Qu S.

Neural Plast. 2016;2016:8941327. doi: 10.1155/2016/8941327. Epub 2016 Feb 14.

Interrelations between cognitive dysfunction and motor symptoms of Parkinson's disease: behavioral and neural studies

Moustafa AA, Chakravarthy S, Phillips JR, Crouse JJ, Gupta A, Frank MJ, Hall JM, Jahanshahi M.

Rev Neurosci. 2016 Jul 1;27(5):535-48. doi: 10.1515/revneuro-2015-0070.

Speech disorders did not correlate with age at onset of Parkinson's disease

Dias AE, Barbosa MT, Limongi JC, Barbosa ER.

Arq Neuropsiquiatr. 2016 Feb;74(2):117-21. doi: 10.1590/0004-282X20160008.

Cholinergic imaging in dementia spectrum disorders

Roy R, Niccolini F, Pagano G, Politis M.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1376-86. doi: 10.1007/s00259-016-3349-x. Epub 2016 Mar 16.

Association Between Autonomic Impairment and Structural Deficit in Parkinson Disease

Chen MH, Lu CH, Chen PC, Tsai NW, Huang CC, Chen HL, Yang IH, Yu CC, Lin WC.

Medicine (Baltimore). 2016 Mar;95(11):e3086. doi: 10.1097/MD.0000000000003086.

Acute tryptophan depletion and Lewy body dementias

Mace JL, Porter RJ, Dalrymple-Alford JC, Collins C, Anderson TJ.

Int Psychogeriatr. 2016 Sep;28(9):1487-91. doi: 10.1017/S1041610216000284. Epub 2016 Mar 18.

Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies

Hauser RA, Abler V, Eyal E, Eliaz RE.

Int J Neurosci. 2016 Oct;126(10):942-6. doi: 10.3109/00207454.2016.1154552. Epub 2016 Mar 18.

Emerging preclinical pharmacological targets for Parkinson's disease

More SV, Choi DK.

Oncotarget. 2016 May 17;7(20):29835-63. doi: 10.18632/oncotarget.8104.

Relearning of Writing Skills in Parkinson's Disease After Intensive Amplitude Training

Nackaerts E, Heremans E, Vervoort G, Smits-Engelsman BC, Swinnen SP, Vandenberghe W, Bergmans B, Nieuwboer A.

Mov Disord. 2016 Aug;31(8):1209-16. doi: 10.1002/mds.26565. Epub 2016 Mar 17.

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.

Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. Epub 2016 Mar 15.

Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With (123) I-FP-CIT SPECT

Bae YJ, Kim JM, Kim E, Lee KM, Kang SY, Park HS, Kim KJ, Kim YE, Oh ES, Yun JY, Kim JS, Jeong HJ, Jeon B, Kim SE.

Mov Disord. 2016 May;31(5):684-92. doi: 10.1002/mds.26584. Epub 2016 Mar 17.

Cryoablation of an atrioventricular nodal reentrant tachycardia in a patient with an implanted deep brain stimulator

Gunawardene M, Meyer C, Willems S, Hoffmann BA.

HeartRhythm Case Rep. 2016 Mar 19;2(3):258-260. doi: 10.1016/j.hrcr.2016.02.003. eCollection 2016 May.

Central Parkin: The evolving role of Parkin in the heart

Dorn GW 2nd.

Biochim Biophys Acta. 2016 Aug;1857(8):1307-1312. doi: 10.1016/j.bbabio.2016.03.014. Epub 2016 Mar 16.

Structure, function and disease relevance of Omega-class glutathione transferases

Board PG, Menon D.

Arch Toxicol. 2016 May;90(5):1049-67. doi: 10.1007/s00204-016-1691-1. Epub 2016 Mar 18.

Challenges of modifying disease progression in prediagnostic Parkinson's disease

Salat D, Noyce AJ, Schrag A, Tolosa E.

Lancet Neurol. 2016 May;15(6):637-48. doi: 10.1016/S1474-4422(16)00060-0. Epub 2016 Mar 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias